News

18 September

Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry

16 September

Democracy violation: European Commission rejects citizens’ initiative to stop TTIP and CETA

24 July

Organic farming practices at Highgrove could offer "princely" contribution to curtailing antibiotic resistance

15 July

School's IN for summer: HAI staff and interns inspired by Utrecht University's course on pharmaceutical policy analysis

23 June

Setting precedents: EMA must get clinical trial data policy right to truly act in public interest

11 June

HAI Europe calls on EMA's Management Board to stand for data transparency

11 June

BMJ statins debate about scientific independence, not rigour

5 June

Hoping for "harmony" on global antibiotic resistance strategy

28 May

Week in review: Outcomes from WHA67

28 May

Progress on access to medicines at WHA67, but WHO funding sorely needed

26 May

World Health Assembly: HAI and ARC intervention on antimicrobial resistance, including antibiotic resistance

26 May

World Health Assembly 67: HAI and KEI intervention on the Consultative Expert Working Group on Research and Development

26 May

World Health Assembly 67: HAI intervention on access to essential medicines

20 May

World Health Assembly 67: HAI intervention on the WHO's framework of engagement with non-state actors

5 May

Action on antimicrobial resistance: It’s about time (and we’re running out)

10 April

Tamiflu review shows desperate need for full clinical trials data transparency

7 April

Governments must ensure Big Pharma’s expansion in Africa doesn’t impede generics supply

3 March

New materials help assess medicines policies and interventions

24 February

A new (and improved) model to regulate pharmaceutical promotion

12 February

Enhancing accountability in the medicines market: The Medicines Transparency Alliance

31 January

Bayer CEO's callous comments highlight failure of current biomedical innovation model

31 January

Leaks and Lies: Pharma’s strategy to derail South Africa’s intellectual property reforms exposed

30 January

Selected R&D demonstration projects disappointing: Innovation models with new incentive mechanisms needed

23 January

Regulation critical to clinical trials data transparency in Europe

25 November

When politicians go to the movies

9 August

True clinical trials transparency? Not quite, EFPIA.

6 August

Conference contemplations: ‘Pharmaceuticals and global health – inequalities and innovation in the 21st century’

21 June

Good week for access to affordable medicines

10 June

Despite concrete steps forward, the ENVI vote on clinical trials regulation falls short on transparency

15 May

Bracing for another delay – open innovation at the WHO?